Intersect's Sinuva implant earns approval, will be regulated as pharmaceutical product
Intersect Ent Inc. has received approval from the FDA for its Sinuva sinus implant, a targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. Upon news of the approval, shares of the Menlo Park, Calif.-based company (NASDAQ:XENT) jumped 15 percent, closing at $32.75. The implant is being regulated as a drug, marking Intersect's first full-fledge foray into the pharma industry.
Livanova to divest CRM business to Microport for about $190M in cash
Livanova plc has agreed to sell its cardiac rhythm management division to medical device manufacturer, Microport Scientific Corp., for $190 million in cash. Livanova will turn its focus to its remaining divisions in cardiac surgery and neuromodulation.
Stryker $215M Vexim buy will rebalance spine market
PARIS A major new deal has been concluded in the world of med-techs. Stryker Corp. of Kalamazoo, Mich., has just made a tender offer for Balma, France-based Vexim SA. The U.S. orthopedics giant paid $215.7 million to acquire this French company specializing in minimally invasive treatment of vertebral fractures, which has been listed on the Euronext Growth market since 2012. "This integration will help us speed up international development of our technology for repairing vertebral fractures and consolidate our position in Europe," Vincent Gardès, CEO of Vexim, told BioWorld MedTech.